Medigen Biotechnology Corp. (TPEX:3176)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.15
+0.10 (0.33%)
At close: Feb 26, 2026
-16.60%
Market Cap 4.20B
Revenue (ttm) 1.59B
Net Income (ttm) -105.96M
Shares Out 139.31M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 463,054
Average Volume 311,214
Open 30.60
Previous Close 30.05
Day's Range 29.80 - 30.65
52-Week Range 23.65 - 36.55
Beta 0.39
RSI 34.57
Earnings Date Mar 27, 2026

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 3176
Full Company Profile

Financial Performance

In 2024, Medigen Biotechnology's revenue was 1.37 billion, an increase of 18.57% compared to the previous year's 1.16 billion. Losses were -204.69 million, -63.53% less than in 2023.

Financial Statements

News

There is no news available yet.